Back to Search
LAUREN RIMSZA, PHARMD
PHARMD
Pharmacist
NPI: 1265164750Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
I023728(AZ)
Research & Publications (20)
Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.
PMID 18544678·Blood·2008
8-other
HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen.
PMID 17454596·Leuk Lymphoma·2007
8-other
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.
PMID 16239429·Blood·2006
8-other
Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.
PMID 14976040·Blood·2004
8-other
Benign B-cell precursors (hematogones) are the predominant lymphoid population in the bone marrow of preterm infants.
PMID 15273444·Biol Neonate·2004
8-other
Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
PMID 19081173·Exp Hematol·2009
8-other
Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation.
PMID 19141865·Blood·2009
8-other
CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression.
PMID 19229048·Haematologica·2009
8-other
A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.
PMID 19373598·Leuk Lymphoma·2009
3-trial
Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations.
PMID 19471018·Blood·2009
4-observational
Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma.
PMID 18698080·Haematologica·2008
4-observational
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
PMID 18765795·Proc Natl Acad Sci U S A·2008
8-other
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
PMID 18385450·Blood·2008
4-observational
Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.
PMID 18413640·J Clin Oncol·2008
3-trial
Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
PMID 18559976·Blood·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 839 W CONGRESS ST
TUCSON, AZ 85745 - Phone
- (520) 670-3909
Quick Facts
- NPI
- 1265164750
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile